ArticleLaryngoscope investigative otolaryngology2026
Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Treatment adherence is a key determinant of outcomes in cancer patients and is influenced by multiple clinical and social factors. Hearing loss (HL) may contribute to communication barriers and treatment disruption. This study aimed to evaluate the relationship between HL and treatment adherence. Materials and Methods: In this single-center prospective observational study, 79 newly diagnosed cancer patients undergoing systemic therapy were evaluated with baseline pure-tone audiometry. HL was categorized by severity. Treatment adherence was assessed based on missed cycles and treatment continuity. Clinical variables, including treatment-related adverse events and caregiver presence, were analyzed using chi-square tests and logistic regression analyses. Results: HL was present in 67.1% of patients. Overall, 55.7% missed at least one treatment cycle. Missed cycles were more frequent in patients with HL ( Conclusion: Treatment adherence appears to be primarily driven by clinical factors, particularly treatment-related toxicity. HL was associated with treatment disruption but was not an independent predictor and may act as a contributing factor. Level of Evidence: 3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.